Hydroxymethylene-substituted chromone-3-carboxaldehydes and process for their preparation
United States Patent 11 1 Kaminsky Apr. 22, 1975 HYDROXYMETl-IYLENE-SUBSTITUTED CHROMONE-I&#39; -CARBOXALDEHYDES AND PROCESS FOR Tl&#39;lElR PREPARATION [75] Inventor: Daniel Kaminsky. Parsippany. NY.  
 [73] Assignee: Warner-Lambert Company. Morris Plains. NJ.  
 [22] Filed: Apr. 18, 1973 [21] Appl. No.: 352.134  
 [52] US. Cl. 260/345.2; 424/283; 260/462 [5 1] Int. Cl C07d 7/34 [58] Field of Search 260/3452 [56] References Cited UNITED STATES PATENTS 3.816.470 6/1974 Tronchce 260/3452 Primary liwmirwr-John M. Ford Attorney. Agent, or FirmAlbert H. G&#39;raddis; Frank S. Chow: Anne M. Kelly [57] ABSTRACT Novel (hydroxymethylene) chromone derivatives of the general formula I:  
 wherein n represents 1 or 2. are prepared by reacting a cycloalkanone II with a boron trifluoride compound and acetic anhydride to obtain novel boron complex intermediates of the formula III:  
  O I F C 0 111 4 Claims, No Drawings I-IYDROXYMETHYLENE-SUBSTITUTED CHROMONE-3-CARBOXALDEHYDES AND PROCESS FOR THEIR PREPARATION According to the novel process of this invention, novel compounds of the general formula I:  
 CI-IOH CHO wherein n represents 1 or 2, are prepared by reacting a cycloalkanone of the formula II:  
  II H wherein n represents 1 or 2, with a boron trifluoride compound and acetic anhydride to obtain novel intermediates of the formula I11:  
 /(&#39;) III boron trifluoride compound used is preferably boron trifluoride etherate. In the second step of the process reaction, an excess of Vilsmeier reagent is reacted with the boron complex intermediate [11.  
  Compounds of this invention having the general formula I above have been found to reduce histaminic responses to antigen challenge by inhibiting antibodyantigen reactions in mammals such as rats or guinea pigs upon oral or parenteral administration. When tested in accordance with the procedure of Mota, Life Sciences, 7, 465, (1963) and Ovary, Proc. Soc. Exptl. Biol. Med., 81, 584, (1952), therapeutic compositions containing the compounds of this invention are effective at dosages of 5 mg to 50 mg/kg of body weight.  
  Pharmaceutical compositions containing the compounds of this invention are therefore useful in the management of allergic reactions such as bronchial asthma. To treat bronchial asthma, a dose of 5 mg to 50 mg/kg by injection or by aerosol administration is suggested. The dosage may be varied depending upon severity of the condition and the weight. age and sex of 5 the patient being treated.  
  In use, the compounds of this invention may be combined with a parcnterally acceptable vehicle. such as a gum tragacanth saline suspension, to provide dosage forms suitable for parenteral administration; or they may be combined with pharmaceutical diluents such as lactose, cornstarch, and the like and formulated into tablet or capsule dosage forms. In order to enhance their therapeutic spectrum, the compounds of this invention may be combined with sympathomimetic agents such as isoprenalinc or combined with steroids such as cortisone and its derivatives.  
  The compounds of this invention also exhibit antisecretory effects and are therefore useful in relieving gastric hyperaeidity. Gastric hyperacidity has generally been described as a factor which contributes to peptic ulcer. The compounds of this invention, when administered to mammals in a manner as described below, have been found to inhibit the gastric secretion of hydrochloric acid and are therefore effective in reducing the resulting acidity in the stomach.  
  At a dosage of 20 mg/kg administered intrape ritoneally, the subject compositions are effective in reducing gastric acidity in the pylorus ligated rat when tested according to the procedure of H. Shay, Gastroenterology, 5, 43, (1945).  
  Pharmaceutical compositions containing the compounds of this invention, are thus indicated in the management of gastric hyperacidity and the treatment of peptic ulcer resulting from such hyperaeidity. For parenteral administration, the pharmaceutical composition of this invention may be administered as aqueous suspensions for intramuscular injection. These are prepared, for example, by suspending the active ingredient in sterile water and packaging in ampules so as to provide a concentration of 1,000 mg of the active ingredient per dosage unit.  
  Generally speaking, the dose required to effectively relieve gastric hyperacidity is within the range of 20 mg/kg of body weight of the mammal being treated. This dosage regimen may be varied depending upon the condition of the patient.  
  Novel boron complex intermediates having the formula III, are useful in preparing the pharmacologically active final compounds having the formula I above.  
  To further illustrate the practice of this invention, the following examples are included:  
 EXAMPLE 1 solution is stirred and the temperature is maintained at about 35C for 1 hour. then cooled and titurated with ether. After standing overnight a solid precipitates and is filtered. The filtrate is concentrated and the residue is reacted with warm ether (Florisil). The addition of Skellysolvc B causes precipitation of additional solid. Total yield is 128 grams, 45.47:, m. p. 7778C.  
 Preparation of 2,2-difluoro-6,7,8,9tetrahydro-4- methyl-5H-cyelohepta[e]-1,3,2-dioxaborin 100 Grams of cycloheptanonc in 195 ml of acetic anhydride&#39; is added, dropwise, to 1 17 ml of boron trifluoride etherate. The reaction is slightly exothermic (35C) and the solution is stirred while maintaining this temperature for 1.5 hours, by heating on a steam bath (vapor evolution) for 1 hour. The reaction is cooled and triturated with a little ether 100 ml). After standing overnight. a solid precipitates which is filtered. The filtrate is concentrated and the residue is extracted with warm ether (Florisil). The addition of Skelly B causes precipitation of additional solid. Total yield is 1 grams. 60.5%. Recrystallized from ether/Skelly B, three times gives light yellow crystals, dried. vac., 25C, 7 hours. m. p. 84-86C.  
 Anal. Calcd. for C,,H,:,BF,O,:  
  C 53.5 Found: C, 53.25; 8.63.18.56  
 EXAMPLE 3 CHOH CHO  
 minutes. The reaction is initially, exothermic. After 10 minutes, it is heated on a steam bath for 2 hours and then poured into about 2 liters of ice water and stirred for 4 hours. A solid precipitates which is filtered, triturated with CH CN, filtered and dried to give 43.2 g (21%) of product. The product is recrystallized from aqueous dimcthylformamide to give a light tan crystalline product, m. p. 226.8C (dec.).  
 Anal. Calcd. for C, H ,O.,: C. 64.08; H. 4.89; O. 31.04 Found: C. 64.22; H. 4.89; O. 30.80  
 CHOH  
 Preparation of 4,5,6,7,8,9-hexahydro-9- (hydroxymethylene)-4-oxo-cyclohepta[blpyran-3- carboxaldehyde To ml of dimethylformamide at 0C, there is added, dropwise, 61.2 g (0.4 mol) of phosphorus oxychloride. To this solution is added 20.2 g (0.1 mol) of the boron difluoride complex prepared in Example ll. The solution is heated on a steam bath for 3 hours and is poured into 1 liter of ice water. A solid precipitates, is filtered and washed with acetone to give 10.2 g (46%) of brown solid. Recrystallization from aqueous dimethylformamide gives a greyish-brown powder, m. p. 202203C (dec.).  
 Anal. Calcd. for C H Q C. 65.44; H. 5.49 Found: C. 65.38; H. 5.33  
  1 claim: l. A process for preparing a compound of the formula l:  
 wherein n represents 1 or 2, which comprises reacting a cyeloalkanone of the formula 11:  
 wherein n represents 1 or 2, with a boron trifluoridc 2. A compound of the formuia 1: compound and acetic anhydride. to obtain an intermediate of the general formula III:  
  O I i z III n(H2 CHO wherein n represents 1 or 2.  
 CH 3. A compound according to claim 2 which is 16.7.8-  
  3 tetrahydro-8-(hydroxymcthylene )-4-oxo-4H- l benzopyran-3-carboxaldehyde. wherein n represents 1 or 2; and reacting boron com- A compound IICCOFdiflg to Claim 2 which i5 55- plex intermediate II! with a Vilsmeier reagent prepared -hcXahydro-9-(hydroxymethylcne )-4-0x0- from phosphorus oxychloride and dimethylformamide cyclohcpta[b]pyran-3-carboxaldehyde. to obtain final compound I.